Oxytrol is a drug owned by Allergan Sales Llc. It is protected by 8 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 26, 2020. Details of Oxytrol's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7081252 | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
Apr, 2020
(4 years ago) |
Expired
|
| US7081250 | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
Apr, 2020
(4 years ago) |
Expired
|
| US7179483 | Compositions and methods for transdermal oxybutynin therapy |
Apr, 2020
(4 years ago) |
Expired
|
| US7081251 | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
Apr, 2020
(4 years ago) |
Expired
|
| US7081249 | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
Apr, 2020
(4 years ago) |
Expired
|
| US6743441 | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
Apr, 2020
(4 years ago) |
Expired
|
| US5601839 | Triacetin as a penetration enhancer for transdermal delivery of a basic drug |
Apr, 2015
(9 years ago) |
Expired
|
| US5834010 | Triacetin as a penetration enhancer for transdermal delivery of a basic drug |
Apr, 2015
(9 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Oxytrol's patents.
Latest Legal Activities on Oxytrol's Patents
Given below is the list of recent legal activities going on the following patents of Oxytrol.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 22 Aug, 2018 | US7179483 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 25 Jan, 2018 | US7081252 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 25 Jan, 2018 | US7081249 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 25 Jan, 2018 | US7081250 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 25 Jan, 2018 | US7081251 |
| Change in Power of Attorney (May Include Associate POA) Critical | 08 Dec, 2010 | US7081252 |
| Correspondence Address Change Critical | 08 Dec, 2010 | US7081252 |
| Change in Power of Attorney (May Include Associate POA) Critical | 28 Jul, 2010 | US7081250 |
| Change in Power of Attorney (May Include Associate POA) Critical | 28 Jul, 2010 | US7081249 |
| Change in Power of Attorney (May Include Associate POA) Critical | 28 Jul, 2010 | US7081251 |
US patents provide insights into the exclusivity only within the United States, but Oxytrol is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Oxytrol's family patents as well as insights into ongoing legal events on those patents.
Oxytrol's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Oxytrol's generic launch date based on the expiry of its last outstanding patent is estimated to be Apr 26, 2020 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Oxytrol Generic API suppliers:
Oxybutynin is the generic name for the brand Oxytrol. 1 company has already filed for the generic of Oxytrol. Check out the entire list of companies who have already received approval for Oxytrol's generic
How can I launch a generic of Oxytrol before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Oxytrol's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Oxytrol's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Oxytrol -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 3.9 mg/24 hrs | 19 Aug, 2008 | 1 | 04 Mar, 2014 | 26 Apr, 2020 | Deferred |
Alternative Brands for Oxytrol
Oxytrol which is used for treating overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence., has several other brand drugs in the same treatment category and using the same active ingredient (Oxybutynin). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Abbvie |
| |||
| Allergan |
| |||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Oxybutynin. Given below is the list of those drugs and companies owning them.
| Drug Owner | Drug Name | |
|---|---|---|
| Abbvie |
| |
| Janssen Pharms |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Oxybutynin, Oxytrol's active ingredient. Check the complete list of approved generic manufacturers for Oxytrol
About Oxytrol
Oxytrol is a drug owned by Allergan Sales Llc. It is used for treating overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence. Oxytrol uses Oxybutynin as an active ingredient. Oxytrol was launched by Allergan in 2003.
Approval Date:
Oxytrol was approved by FDA for market use on 26 February, 2003.
Active Ingredient:
Oxytrol uses Oxybutynin as the active ingredient. Check out other Drugs and Companies using Oxybutynin ingredient
Treatment:
Oxytrol is used for treating overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence.
Dosage:
Oxytrol is available in film, extended release form for transdermal use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 3.9MG/24HR | FILM, EXTENDED RELEASE | Prescription | TRANSDERMAL |